Deston Therapeutics

Deston Therapeutics was a specialty pharmaceutical company headquartered in Fort Worth, Texas, focused on acquiring and commercializing branded prescription products. The company primarily targeted the central nervous system (CNS) and inflammatory therapeutic markets. Its lead commercial product was Pexeva (paroxetine mesylate), a selective serotonin reuptake inhibitor (SSRI) indicated for depression and various anxiety disorders. Additionally, the company marketed Veripred 20, a liquid formulation of prednisolone used for treating a wide range of inflammatory and autoimmune conditions. Deston's business model centered on identifying undervalued or niche assets that could benefit from focused sales and marketing efforts. In 2013, Deston Therapeutics was acquired by Sebela Pharmaceuticals, and its operations were subsequently integrated into the acquiring firm's portfolio.